加载中
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
前收盘价
US$154.49
+US$1.97 · +1.29%
盘中时间采用ET。市场数据可能有所延迟。
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
日内区间
当前US$154.49
52周区间
当前US$154.49
盘中时间采用ET。市场数据可能有所延迟。
Belite Bio, Inc. is a clinical-stage biopharmaceutical company focused on the discovery and advancement of novel therapies. The firm's primary therapeutic areas include atrophic age-related macular degeneration and autosomal recessive Stargardt disease. Its flagship drug candidate, LBS-008, is an investigational oral medication administered once daily. Currently undergoing Phase 3 clinical trials, LBS-008 is engineered to modulate vitamin A delivery to the eye, thus preventing the accumulation of detrimental vitamin A metabolites in ocular tissues. Furthermore, Belite Bio is advancing LBS-009, an oral anti-retinol binding protein 4 therapy, through preclinical development. This therapy targets various liver ailments, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes. Founded in 2016, Belite Bio, Inc. is headquartered in San Diego, California, and operates as a subsidiary of Lin Bioscience International Ltd.
日内区间
当前US$154.49
52周区间
当前US$154.49
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 研究与开发 | 4537.7万 USD | 2993.9万 USD | 2484.4万 USD | 886.9万 USD | 741.9万 USD |
| 销售、一般及管理费用 | 3883.1万 USD | 1005.7万 USD | 682.4万 USD | 395.2万 USD | 237.8万 USD |
| 营业费用 | 8420.8万 USD | 3999.6万 USD | 3166.8万 USD | 1282.1万 USD | 979.7万 USD |
| 利息收入 | — | 373.7万 USD | 7.4万 USD | 2.3万 USD | 5000 USD |
| 利息支出 | — | 2万 USD | 2.5万 USD | 1.6万 USD | — |
| 折旧和摊销 | 46.4万 USD | 44.9万 USD | 39.9万 USD | 19.8万 USD | 3万 USD |
| 营业利润 | −8420.8万 USD | −3999.6万 USD | −3166.8万 USD | −1282.1万 USD | −979.7万 USD |
| 净利润 | −7761.1万 USD | −3614.4万 USD | −3163.2万 USD | −1264.8万 USD | −966.6万 USD |
公司数据更新于 2026年10月11日。
近期已公布业绩
报告持有此股票敞口的交易所交易基金。
State Street SPDR Portfolio Emerging Markets ETFSPEM459.41万0.03%175.23亿 USD0.07%US$52.21+1.32%
ICBC CSOP S&P New China Sectors ETF3167.HK77.32万0.22%3.58亿 HKD1.13%HK$55.98+1.49%
ActivePassive International Equity ETFAPIE64.98万0.06%11.41亿 USD0.45%US$38.56+0.65%
Fidelity Nasdaq Composite Index ETFONEQ57.15万0.01%109.4亿 USD0.21%US$107.81+0.63%
State Street SPDR S&P China ETFGXC48.68万0.11%4.46亿 USD0.59%US$86.47+1.87%
Virtus Biotech Clinical Trials ETFBBC35.03万0.85%4099.65万 USD0.65%US$44.1456+2.08%
Even Herd Long Short ETFEHLS19.78万0.34%5883.5万 USD2.62%US$25.4482+0.28%
Morgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSM6.6万0.01%6.94亿 USD0.89%US$57.70+0.92%State Street SPDR Portfolio Emerging Markets ETFSPEMICBC CSOP S&P New China Sectors ETF3167.HKActivePassive International Equity ETFAPIEFidelity Nasdaq Composite Index ETFONEQState Street SPDR S&P China ETFGXCVirtus Biotech Clinical Trials ETFBBCEven Herd Long Short ETFEHLSMorgan Stanley Pathway Funds - Small-Mid Cap Equity ETFMSSMAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
